Local Transformations of Androgens into Estradiol by Aromatase P450 Is Involved in the Regulation of Prolactin and the Proliferation of Pituitary Prolactin-Positive Cells

Maria José García Barrado2,3,9, Enrique J. Blanco1,2,9, Marta Carretero Hernández1, María Carmen Iglesias Osma2,3, Manuel Carretero4, Julio J. Herrero5, Deborah Jane Burks6,9, José Carretero1,2,9

1 Department of Human Anatomy and Histology, Faculty of Medicine, University of Salamanca, Spain, 2 Laboratory of Neuroendocrinology, Institute of Neurosciences of Castilla y León, and Laboratory of Endocrine-Metabolic Diseases of IBSAL, University of Salamanca, Spain, 3 Department of Physiology and Pharmacology, Faculty of Medicine, University of Salamanca, Spain, 4 Faculty of Human and Social Sciences, University Pontificia of Salamanca, Spain, 5 Department of Surgery, Faculty of Medicine, University of Salamanca, Spain, 6 Laboratory of Neuroendocrinology, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain

Abstract

In previous studies we demonstrated the immunohistochemical expression of aromatase in pituitary cells. In order to determine whether pituitary aromatase is involved in the paracrine regulation of prolactin-producing pituitary cells and the physiological relevance of pituitary aromatase in the control of these cells, an in vivo and in vitro immunocytochemical and morphometric study of prolactin-positive pituitary cells was carried out on the pituitary glands of adult male rats treated with the aromatase antagonist fadrozole. Moreover, we analyzed the expression of mRNA for the enzyme in pituitary cells of male adult rats by in situ hybridization. The aromatase-mRNA was seen to be located in the cytoplasm of 41% of pituitary cells and was well correlated with the immunocytochemical staining. After in vivo treatment with fadrozole, the size (cellular and nuclear areas) of prolactin cells, as well as the percentage of prolactin-positive cells and the percentage of proliferating prolactin cells, was significantly decreased. Moreover, fadrozole decreased serum prolactin levels. In vitro, treatment with fadrozole plus testosterone induced similar effects on prolactin-positive cells, inhibiting their cellular proliferation. Our results suggest that under physiological conditions aromatase P450 exerts a relevant control over male pituitary prolactin-cells, probably transforming testosterone to estradiol in the pituitary gland.

Citation: García Barrado MJ, Blanco EJ, Carretero Hernández M, Iglesias Osma MC, Carretero M, et al. (2014) Local Transformations of Androgens into Estradiol by Aromatase P450 Is Involved in the Regulation of Prolactin and the Proliferation of Pituitary Prolactin-Positive Cells. PLoS ONE 9(6): e101403. doi:10.1371/journal.pone.0101403

Editor: Raul M. Luque, University of Cordoba, Spain
Received February 5, 2014; Accepted June 5, 2014; Published June 30, 2014
Copyright: © 2014 García Barrado et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was financially supported by the FIS Spanish program No. PI0-21803. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: barrado@usal.es
9 These authors contributed equally to this work.

Introduction

Of the two pathways through which androgens are metabolized -reduction and aromatization- the latter depends on the presence of an enzyme (aromatase P450) belonging to the family of cytochrome P450.

There is growing awareness that androgens and estrogens play general metabolic roles that are not directly involved in reproductive processes. Estrogen is no longer considered solely an endocrine factor but instead is produced in a number of extra-gonadal sites and acts locally at these sites in a paracrine and autocrine fashion. These sites include breast, bone, vasculature, and brain. Within these sites, the action of aromatase can generate high levels of estradiol locally, without significantly affecting circulating levels [1,2].

At our laboratory, we have demonstrated the expression of aromatase in the rat pituitary gland. This expression was related to the sex and age of the animals. Moreover, we reported a very strong correlation between the pituitary expression of aromatase and the incidence of spontaneous prolactinomas in old rats [3] and humans [4]. Similar results were later reported by different authors in non-tumoral pituitaries of humans and different animal species [3–11] and in human prolactinomas [12]. However, the physiological relevance of aromatase and the possible aromatization of testosterone to estradiol in the regulation of pituitary hormones are not well known.

Because estradiol is an important physiological regulator of pituitary prolactin secretion [13–19] and is involved in the control and proliferation of prolactin-producing cells [20], the aim of the present study was to analyze the relevance of the regulatory role of the local transformation of androgens into estradiol by aromatase in the maintenance of the population of prolactin cells in the male pituitary gland, through the pituitary aromatization of testosterone to estradiol. For this purpose, the in vivo or in vitro effects of aromatase on the pituitary glands of adult male rats were blocked by treatment with the aromatase antagonist fadrozole.

PLOS ONE | www.plosone.org 1 June 2014 | Volume 9 | Issue 6 | e101403

CrossMark
**Materials and Methods**

**Animals**

Animal experimentation was performed according to the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH Publication No. 85–23, revised 1996). All procedures were approved by the Committee for the Care and Use of Animals of the University of Salamanca, which ensures compliance with national and European legislation regarding the use of animals in research (Spanish RD 53/2013 and 2010/63/EU).

Fifty Wistar male adult rats (175–200 g body weight) were used. The animals were divided into 5 groups of 10 animals each according to treatment: (a) untreated animals; (b) control 1-dose animals, treated intramuscularly with 1 dose of 200 μl of saline; (c) control 5-dose animals, treated intramuscularly with 5 doses (1 dose per day) of 200 μl of saline; (d) 1-dose-treated animals, treated intramuscularly with 1 dose of 0.5 mg of fadrozole in 200 μl of saline; (e) 5-dose-treated animals, treated intramuscularly with 5 doses (1 dose per day) of 0.5 mg of fadrozole in 200 μl of saline.

During the experiments, all groups were kept under standard stabilizing conditions (temperature 21±2°C, relative humidity 50±5%, controlled photoperiod of 14 h light/10 h darkness, food and water ad libitum with a balanced rat/mouse maintenance diet (Panlab).

**Sample collection and processing**

Animals were sacrificed between 10.00 and 11.00 h by decapitation after anaesthesia by isoflurane inhalation. The pituitary glands were carefully dissected out and immediately fixed in a solution of 13% saturated picric acid in 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4, for 24 h. Then, they were dehydrated in ethanol, cleared with xylene, and embedded in paraffin in order to obtain coronal serial sections of 5 μm thickness. These were placed on slides treated with gelatin-chrome alum and were then used for the immunohistochemical study. After sacrifice, blood samples were obtained to determine serum prolactin levels.

**Pituitary cultures**

Following anaesthesia with isoflurane, 5 male Wistar rats (175–200 g) were killed by decapitation and the anterior pituitary glands were removed and washed in Earle’s balanced salt solution. Enzymatic dispersion was carried out by incubation for 15 minutes at 37°C in Hank’s solution to which 0.15% MgCl₂, 0.1% papain, 0.01% DNase and 0.1% of neutral protease had been added. Mechanical dispersion was achieved by passing the pituitaries through Pasteur pipettes and 20 to 22 gauge needles. After centrifugation, the supernatant was removed and the cells were suspended in an appropriate volume of Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% calf serum, 2.5% foetal calf serum, 2% L-glutamine, 1000 IU/ml of penicillin and 1000 IU/ml of streptomycin. The cells were seeded on 60 culture chamber slides (Nunc, 1 ml) at a final concentration of 2.5×10⁴ cells/ml and incubated at 37°C in a 5% CO₂/95% air atmosphere for 7 days. On the 4th day of incubation the medium was changed by fresh medium. On the 7th day, cultures were treated with 10⁻¹⁰ M testosterone, 10⁻⁶ M Fadrozole and incubated for 1, 3, 6 or 12 hours (five chambers per treatment and time-point assayed). Previously, testosterone was diluted in ethanol, the final concentration of ethanol in the treated and control dishes being 0.0027%.

After treatment, the chambers were carefully washed with Dulbecco’s sterile PBS and then the cells were fixed in Somogy’s solution for 1 hour, followed by careful rinsing in PBS. In order to validate the results obtained, two pituitary cultures were made under identical experimental conditions.

**Serum prolactin determination**

From serum samples, prolactin was assayed by double antibody RIA using the Dipesarat hormone kit according to the manufacturer’s instructions. The intra- and inter-assay coefficients of variation were lesser than 3% and 6% respectively.

**Western blotting**

For Western blotting, the pituitary glands were dissected from adult rats and immediately frozen. Tissues were then disrupted by homogenization in lysis buffer (137 mM NaCl, 10 mM TB, pH 7.4, 10% glycerol and 1% Triton X-100, containing a cocktail of protease inhibitors). Insoluble material was removed from the lysates by centrifugation at 10,000 rpm for 10 min. Protein concentrations were determined using the standard Bradford assay. Fifty μg of total protein from each rat sample was separated by 10% SDS-PAGE. Following electrophoresis, proteins were transferred to nitrocellulose and then blocked for 1 h with 5% non-fat dry milk in PBS. The nitrocellulose membranes were then incubated overnight with either preabsorbed anti-aromatase serum or anti rat aromatase P450 rabbit polyclonal serum (Rb-SG 872 Sigma), diluted 1:500. Blots were subjected to 3×13 min washes with PBS and then incubated for 1 h with HRP-labelled secondary antibodies (1:10,000 in PBS). Following extensive washing, the blots were revealed by Amersham ECL western blotting detection reagents (Amersham). The average exposure time was 2 min. Western blotting revealed the existence of a protein with a molecular weight of around 50 kDa in the pituitary gland (Figure 1a).

For preabsorption tests, in western blotting or immunohistochemistry diluted anti-aromatase serum (1:500) was preabsorbed (24 h at 4°C) with the peptide sequence C-EIIFRHIFNTPFLQC [21], corresponding to residues 489–503 of rat aromatase (50 μg peptide/ml antibody solution), which was used to obtain rabbit polyclonal anti rat aromatase P450 rabbit polyclonal serum (Rb-SG 872 Sigma). Positive controls from ovary and prolactinoma (Figure 1b) were included.

**Immunohistochemistry**

Immunohistochemical studies were performed using the streptavidin-peroxidase method in single immunostaining, or the strepto-avidin-peroxidase and PAP methods in double immunostaining. The sources and working dilutions of the primary antibodies were as follows: anti rat aromatase P450 rabbit polyclonal serum (Rb-SG 872 Sigma, diluted 1:500), anti-Proliferating Cell Nuclear Antigen (PCNA) monoclonal antibody (Dako, diluted 1:3000) and anti-prolactin polyclonal antibody (Dako, diluted 1:1000).

Single immunostaining was carried out for aromatase and prolactin: Primary antibodies were incubated with tissue sections at 4°C overnight. After washing, the slides were incubated for 45 min at room temperature with biotinylated-goat anti-rabbit or mouse IgG (Caltag, diluted at 1:100 in TBS) and then for 45 min at room temperature with streptavidin-peroxidase complex (Caltag, diluted at 1:150). The reaction was developed with freshly prepared 3,3’-diaminobenzidine (Sigma, 0.024% in TB buffer plus 0.3% H₂O₂). The washes and antibody dilutions were made in TBS: HCl-Trizma, 0.05 M, pH 7.4, plus 0.8% NaCl.
To study PCNA-positive cells and to determine the PCNA-Prolactin labelling index, a double labelling immunohistochemical method for PCNA and prolactin was developed. Endogenous peroxidase was blocked with H$_2$O$_2$ in methanol and non-specific reactions of the secondary antibody by incubation in normal goat serum (Dako, diluted 1:30). Sections were incubated overnight at 4°C with mouse anti-PCNA monoclonal antibody (PC10, Dako, diluted 1:3000 in TBS). Biotinylated goat anti-mouse IgG (Dako, diluted 1:100) and Avidin-Biotinylated horseradish peroxidase complex (ABC kit, Dako, diluted 1:100) were successively applied at room temperature for 40 min and 30 min, respectively. The reaction was developed in freshly prepared 3,3'-DAB (0.025% in TB buffer containing 0.03% of H$_2$O$_2$). Following PCNA immunolabelling, the peroxidase-antiperoxidase (PAP) reaction was performed for the detection of prolactin, The reaction was allowed to progress by incubation for 40 min at room temperature with swine anti-rabbit IgG (Dako, diluted 1:100), and later with incubation with soluble peroxidase anti-peroxidase complex (Dako diluted 1:100) were successively applied at room temperature for 40 min and 30 min, respectively. The reaction was developed in freshly prepared 3,3'-DAB (0.025% in TB buffer containing 0.03% of H$_2$O$_2$).

Preabsorption tests with prolactin and tests replacing the specific serum by normal non-immune rabbit serum abolished the reaction. Using ELISA, the specificity of swine anti-rabbit IgG was lower than 1% for rat and mouse IgG and 100% for rabbit IgG. For the washes and dilutions of the sera, TB buffer (0.05 M, pH 7.4) containing 0.8% NaCl was used. The reaction was developed in freshly prepared 4-chloro-1-naphthol (1.7 x 10$^{-3}$ M in 3% absolute ethanol and TB-buffer containing 0.3% H$_2$O$_2$).

Preabsorption tests with prolactin and tests replacing the specific serum by normal non-immune rabbit serum abolished the reaction. Using ELISA, the specificity of swine anti-rabbit IgG was lower than 1% for rat and mouse IgG and 100% for rabbit IgG. For the washes and dilutions of the sera, TB buffer (0.05 M, pH 7.4) containing 0.8% NaCl was used. The reaction was developed in freshly prepared 4-chloro-1-naphthol (1.7 x 10$^{-3}$ M in 3% absolute ethanol and TB-buffer containing 0.3% H$_2$O$_2$).

**In situ hybridization**

These studies were performed using a non-isotopic method involving the immunocytochemical detection of biotin using the streptavidin-biotin-peroxidase method. To accomplish in situ hybridization, the sense biotinylated oligonucleotide 5’BIO-gag gat gac gtg att gag ggc tac ceg ttg aat gga act aac att ctg aac atc gga, and antisense 5’ Bio-ctc cta ctg cac taa ctg ccg atg ggc caa tgt ttc tct tga tgt tag taq gac tgt tag cca, 100% specific to rat aromatase P450 according to the GenBank data base (accession number, M33986), was used as probes [21].

Slides were prehybridized in Omnibuffer for 30 minutes at 37°C. Hybridization with the biotinylated-probe (100 pg/ml in Omnibuffer) was carried out using a Hybaid thermocycler overnight at 37°C. The reaction was stopped by washes in 1 x SSC at 54°C for 20 min, 1 x SSC at room temperature for 20 minutes, and for 20 minutes in PBS (0.01 M, pH 7.4, plus 0.8% NaCl). Biotin was detected using monoclonal anti-biotin antibodies (Roche, 1:250 in TBS: 0.05 M HCl-Trizma, pH 7.4, plus 0.8% NaCl) overnight at 4°C in a humidity chamber, followed by biotinylated goat anti-mouse (Caltag, 1:250 in TBS). The reaction was amplified using the tyramide amplification kit (Dako) according to the instructions of the manufacturers. The final reaction was developed with 3,3'-diaminobenzidine (0.025 M, Sigma, in 0.05 M TB-HCl buffer, pH 7.4) to which 0.03% H$_2$O$_2$ had been added. The slides were counterstained using Mayer’s acid haematoxylin.

As controls, hybridization with sense probe, omission of the probe and pretreatment with RNase were performed, no reaction being observed in any case (Figures 1e and 1f).
Quantification of aromatase mRNA-expressing cells

The percentage of aromatase mRNA-expressing cells was quantified in each animal following the double-blind procedure. Briefly, eight thousand cells (with intact cellular and nuclear profiles) were counted from 20 sections separated from one another by at least 50 μm (400 cells/section), chosen randomly from all parts of the gland, after which the percentage of reactive cells was calculated.

Quantification of immunoreactive cells

Immunopositive cells were quantified following the double-blind procedure. Briefly, in vivo four thousand cells (with intact cellular and nuclear profiles) were counted from 20 sections separated from one another by at least 50 μm (200 cells/section), chosen randomly from all parts of the gland, after which the percentage of aromatase-, prolactin- or PCNA and prolactin-positive cells was calculated. In vitro, 400 cells chosen randomly from all parts of the dish were counted, and the percentage of prolactin-positive cells with respect to the total number of cells, and the percentage of PCNA- and prolactin-positive cells, of total prolactin-positive cells, was calculated.

Morphometry

Using the Image J software (NIH), 500 randomly chosen prolactin-positive cells per animal, or 100 randomly chosen prolactin-positive cells per dish were measured for morphometric study (cells were considered when the nuclear and cellular profiles in the plane of section or focus were clearly distinguished). Cellular and nuclear areas were determined.

Statistical analyses

For each parameter evaluated, the values obtained, after each treatment, were processed statistically using the SPSS software and the differences observed among mean values were compared using analysis of variance, accepting p values of <0.05 as significant for the Scheffé F test. Results are expressed as arithmetic means ± standard error of the mean.

Results

Aromatase P450 expression in the pituitary gland of male adult rats

Western blotting. The image in Figure 1 shows that the hypophysis of the adult male rat contains a protein of 52 kDa, which is detected with the Rh-872 antibody, specific for rat aromatase P450. The immunoblot did not appear after pre-absorption (Figure 1a).

Immunohistochemistry. As shown in Figure 1c, in many hypophyseal glandular cells of adult male rats the presence of the enzyme was detected by means of immunohistochemistry.

In situ hybridization. Figure 1d shows that in many hypophyseal cells of adult male rats it is possible to detect the presence of aromatase mRNA by in situ hybridization (controls: absence of the probe –Fig. 1e, and sense aromatase Fig. 1f).

In vivo effects of fadrozole

Prolactin levels. The untreated and control (saline-treated) animals showed similar basal prolactin serum levels (see Figure 2d). Treatment with fadrozole led to a clear and significant (p<0.01) decrease in serum prolactin levels, and significant differences were found among animals treated with one dose of fadrozole and those treated with 5 doses (p<0.05).

Morphological findings in prolactin-positive cells. The prolactin cells of the untreated animals were found scattered throughout the pituitary gland, with a predominance of polygonal and oval shapes, with scant but very reactive cytoplasm and a central nucleus. There were also cells with a polarized nucleus. (Figure 2a and arrows in Figure 2b). In both groups of treated animals (1 and 5 doses of fadrozole) the intensity of the cytoplasmic reaction of prolactin-positive cells was lower than in the untreated or control animals (arrows in Figure 2c).

Morphometric findings in prolactin-positive cells. The mean cellular area of the prolactin-positive cells (Figure 2e) of the untreated animals was 74.58±1.63 μm². Non-significant variations were observed after treatment with saline (1 dose: 73.11±1.99 μm², and 5 doses: 77.08±1.33 μm²). Treatment with fadrozole decreased the cellular area of prolactin-positive cells significantly (1 dose: 50.4±1.35 μm²; 5 doses: 43.89±1.36 μm² p<0.01 with respect to untreated and saline-treated animals). Very similar results were found when mean nuclear areas (Figure 2f) were analysed, with similar values for untreated animals (20.91±0.51 μm²) and saline-treated animals (1 dose: 21.62±0.24 μm²; 5 doses: 20.48±0.38 μm²) and significant decreases (p<0.01 with respect to untreated and saline-treated animals) following fadrozole treatment (1 dose: 10.48±0.26 μm²; 5 doses: 10.41±0.18 μm²).

Percentage of prolactin-positive cells. The percentage of prolactin-positive cells (Figure 3c) in untreated animals was 41.9±0.8%. This percentage decreased after salmine treatment. However, this decrease was only significant after 1 dose of saline (34.7±0.7, p<0.05 with respect to untreated animals) but not after 5 doses (40.3±0.8). Treatment with fadrozole significantly decreased the percentages of prolactin-positive cells after 1 dose (26.8±0.5, p<0.01 with respect to untreated and saline-treated animals) and this effect was more evident after 5 doses (20.0±0.5, p<0.01 with respect to untreated and saline-treated animals, and p<0.05 with respect to fadrozole 1-dose treated animals).

Percentage of prolactin-proliferating cells. Prolactin-proliferating cells appeared with brown-stained nuclei and a dark blue-stained cytoplasm (Figures 3a, 3b). The percentage of prolactin-proliferating cells (Figure 3d) was relatively low in untreated males (4.7±0.2) and very similar values were found for the saline 1-dose control animals: 5.3±0.2 and saline 5-dose rats: 4.0±0.1. Treatment with fadrozole significantly decreased the percentages of prolactin-positive cells after 1 dose (2.8±0.1, p<0.01 with respect to untreated and saline 5-dose animals) than in the animals treated with 1 dose of the aromatase antagonist (3.6±0.1, p<0.05 with respect to untreated, saline 1-dose and fadrozole 5-dose animals).

In vitro effects of fadrozole

Morphometric findings in prolactin-positive cells. No statistically significant variations in the cellular area of prolactin-positive cells were found following treatment with fadrozole or testosterone alone (Figure 4d). Treatment with fadrozole plus testosterone significantly decreased the size of the prolactin-positive cells with respect to the other treatment groups analyzed. This effect was more relevant in the animals treated with 5 doses of fadrozole (2.8±0.1, p<0.01 with respect to untreated and saline 5 doses animals) than in the animals treated with 1 dose of the aromatase antagonist (3.6±0.1, p<0.05 with respect to untreated, saline 1-dose and fadrozole 5-dose animals).

In vivo effects of fadrozole

Morphometric findings in prolactin-positive cells. The variations observed among the control cultures (Figure 4a) and those treated with fadrozole or testosterone alone (Figure 4b) did not reach statistical significance (Figure 4c). In contrast, treatment with fadrozole plus testosterone (Figure 4c) significantly decreased the percentage of such cells as from 3 hours (p<0.01. Figure 4c).
Percentage of prolactin-proliferating cells. No significant
differences were observed between the control cultures and those
-treated with fadrozole or testosterone alone (Figure 4f). The
treatment with fadrozole plus testosterone (Figure 4c) significantly
decreased the percentage of proliferating prolactin-positive cells as
from the first hour of treatment (p < 0.01. Figure 4f).

Discussion

Previous findings from our laboratory suggest an important role
of aromatase in the regulation of pituitary hormones, because we
observed that aromatase P450 is expressed in the rat pituitary
gland; that this expression is modified by sex and age, and that it
could be involved in the genesis of spontaneous prolactinomas in
old rats [3] or humans [4–12]. Moreover, aromatase mRNA has
been reported in pituitary cells using in situ hybridization in trout
[5]. These findings have been confirmed by other laboratories, in
the sense that aromatase is expressed in the pituitary gland of
different animal species, including humans [6,10,22], and that
variations in its expression are regulated by gonadal steroids [6]
because testosterone increased the expression but estradiol
decreased it.

However, the role of aromatase in the regulation of pituitary
hormones or cells is not well established, although several lines of
evidence suggest the possibility that estrogens generated locally by aromatization could be involved in the activation of anterior pituitary mitotic activity [23]. Although androgens have an inhibitory effect on prolactin, the percentage of prolactin-producing cells in the pituitary glands of adult male rats is high [24]. Because the expression of pituitary aromatase is higher in males than in females [25], the local aromatization of testosterone to estradiol in the pituitary of males could be involved in the regulation of the population of prolactin-producing cells.

Figure 3. Effects of in vivo treatment with fadrozole on the cellular proliferation of prolactin-positive cells. a) Double labelled immunohistochemistry for prolactin (dark blue-grey) and PCNA (brown). In untreated animals, few prolactin-positive cells are labelled for PCNA (arrow). Scale bar: 12 μm. b) After 5 doses of fadrozole it is uncommon to find cells labelled jointly for PCNA and prolactin (arrow points to PCNA- but not prolactin-positive cells). Scale bar: 12 μm. c) The percentage of prolactin-positive cells decreases significantly with respect to the untreated or control animals after 1 dose (**p<0.01 with respect to untreated animals, and p<0.05 with respect to control animals) or 5 doses (**p<0.01 with respect to untreated and control animals and p<0.05 with respect to 1 dose of the fadrozole treated animals). After 1 dose of saline the percentage decreases with respect to untreated animals (#p<0.05), but not after 5 doses. d) Fadrozole decreases the proliferation of prolactin-positive cells (*p<0.05 with respect to untreated and control animals; **p<0.01 with respect to untreated and control animals and p<0.05 with respect to 1 dose of fadrozole-treated animals).

doi:10.1371/journal.pone.0101403.g003
findings observed in the present study seem to support such a notion.

Androgenic effects on prolactin cells and secretion of the hormone are different, depending on whether the androgen is susceptible to its aromatization. Non-aromatizable androgens are inhibitors or hardly exert effects on prolactin producing pituitary cells, while aromatizable androgens increase the release of prolactin [26] and the levels of prolactin mRNA [27]. These functional changes obtained with doses of testosterone similar to those used in our study (10^{-6} to 10^{-2} M) are not accompanied by

**Figure 4. Effects of in vitro treatment with fadrozole on prolactin-positive cells.** Double immunocytochemical staining for PCNA (brown) and prolactin (dark blue-grey) in control dishes a), testosterone-treated dishes b), and testosterone- and fadrozole-treated dishes c). Scale bar: a,b,c: 50 µm. d) Plot showing the decrease in cellular area at the different time-points assayed; from 3 to 12 hours of treatment with testosterone and fadrozole a significant decrease (*p<0.01) was observed. e) The percentage of prolactin-positive cells decreases as from 3 to 12 hours of treatment with testosterone and fadrozole (*p<0.01). f) The percentage of PCNA- and prolactin-positive cells, out of the total number of prolactin-positive cells, decreases significantly from 1 to 12 hours of treatment with testosterone and fadrozole (*p<0.01).

doi:10.1371/journal.pone.0101403.g004
changes in cell growth [26]. These findings are consistent with those observed in our study, in which testosterone did not significantly modify the size or proliferation of prolactin-positive cells.

The in vitro inhibitory effects observed following treatment with fadrozole and testosterone jointly could be explained in terms of the androgenic effects of testosterone or because testosterone could be metabolized into non-aromatizable androgens.

Fadrozole is a potent non-steroidal inhibitor of aromatase P450, and it has been shown that a dose of 4 mg/Kg induces uterine atrophy without inducing adrenal hypertrophy [28]. In our in vivo study, we used a lower dose, within the ranges tested by other authors [29,30] in a similar protocol to that described in [31], although slightly higher than the one used by these authors, with the aim of obtaining security inhibition rates higher than 90% [28], but not to induce atrophy of the organs of the reproductive system.

Estradiol is an important regulator of pituitary prolactin. It is well documented in the literature that estradiol, through coupling of the estrogen-receptor complex to the specific response element to estrogens in the promoter of the gene encoding prolactin synthesis, induces increases in prolactin synthesis through a biphasic transcription that culminates in an increase in the prolactin mRNA; this has a direct action on the gene able to alter the transcription [32–43]. Moreover, estradiol stimulates the secretion of prolactin [14,19,44–46]. These effects are accompanied by morphological changes such as hypertrophy of the cellular organelles [47–51], with evidence of hyperactivity and hyperplasia of prolactin-producing cells [34,52,53]. Furthermore, estradiol induces the proliferation of pituitary prolactin-producing cells [20,54–58].

In the present study, after in vivo treatment with the aromatase antagonist fadrozole, highly significant changes were observed in proliferative prolactin-positive cells: decreases in the intensity of the immunohistochemical reaction in the pituitary of male rats, and pituitary aromatase is probably involved in the proliferation and hormonal secretion is decreased, as demonstrated in previous studies [59].

As may be deduced from the results of this study, and in accordance with previous studies, aromatase is clearly expressed in the pituitary of male rats, and pituitary aromatase is probably expressed in different endocrine cells, including prolactin-producing cells [6]. This observation is very relevant because in the male pituitary aromatizable androgens can be metabolized to estrogens by means of aromatase; thus, estrogens can modulate and regulate the population of prolactin-producing cells, accounting for the important percentages of these cells in the male pituitary [24].

Because estradiol induces effects opposite those of fadrozole on prolactin cells, and since the aromatization of testosterone to estradiol is mediated by aromatase, the effects of fadrozole observed in our study suggest that aromatase would be involved physiologically in the regulation of the pituitary prolactin-producing cells of male rats, transforming testosterone to estradiol at the pituitary level.

**Author Contributions**

Conceived and designed the experiments: MGB EJB MCH MJIO JC. Performed the experiments: EJB JJH MG MCH JC. Analyzed the data: EJB JC MCH MJIO. Contributed reagents/materials/analysis tools: MCH JC DJB. Wrote the paper: JC EJB MGB MJIO DJB.

**References**

1. Simpson ER, Davis SR (2001) Minireview: aromatase and the regulation of estrogen biosynthesis–some new perspectives. Endocrinology 142: 4539–4594.

2. Vona-Davis I, Rose DP (2013) The Obesity-Inflammation-Esacoid Axis in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia 18: 291–307.

3. Carretero J, Burks DJ, Vazquez G, Rubio M, Hernandez E, et al. (2002) Expression of aromatase P450 is increased in spontaneous prolactinomas of aged rats. Pituitary 5: 3–10.

4. Carretero J, Blanco EJ, Carretero M, Carretero-Hernandez M, Garcia-Barrado MJ, et al. (2013) The expression of ARB1 correlates with cellular proliferation in human prolactinomas. Ann Anat 195: 253–259.

5. Menuet A, Anglade I, Le Guevel R, Pellegrini E, Paez F, et al. (2003) Distribution of aromatase mRNA and protein in the brain and pituitary of female rainbow trout: Comparison with estrogen receptor alpha. J Comp Neurol 460: 180–193.

6. Galmiche G, Richard N, Corvaisier S, Kottler ML (2006) The expression of aromatase in gonadotrophs is regulated by estradiol and gonadotropin-releasing hormone in a manner that differs from the regulation of luteinizing hormone. Endocrinology 147: 4234–4244.

7. Goto-Kazeto R, Kight KE, Zohar Y, Place AR, Trant JM (2004) Localization and expression of aromatase mRNA in adult zebrafish. Gen Comp Endocrinol 131: 72–84.

8. Nocilado JN, Elizur A, Vainan A, Carrick F, Levasi-Sivan B (2007) Cytochrome P450 aromatase gene expression in human pituitary before and after luteinization: adenosine

9. Heidari Z, Hosseinpanah F, Shirazian N (2010) Achievement of fertility in an infertile man with resistant macroprolactinoma using high-dose bromocriptine and a combination of human chorionic gonadotropin and an aromatase inhibitor. Endocr Prat 16: 669–672.

10. Kadioglu P, Oral G, Sayitoğlu M, Erensoy N, Senel B, et al. (2008) Aromatase cytochrome P450 enzyme expression in human pituitary. Pituitary 11: 29–35.

11. Trubirsha A, Kroupova H, Wuertz S, Kloas W (2012) Up-regulation of aromatase cytochrome P450 in rat ovarian granulosa cells before and after luteinization: adenosine

(Rutilus rutilus): evidence for an important role of brain-type aromatase (cyp19a1b) in the pituitary. Gen Comp Endocrinol 178: 529–538.

12. Akinci H, Kapucu A, Dar KA, Celik O, Tutunculer B, et al. (2013) Aromatase cytochrome P450 enzyme expression in prolactinomas and its relationship to tumor size, cell type, and hormonal secretion. Endocr Pract 19: 396–392.

13. Barracough CA, Camp P, Weiland N, Akabori A (1986) Stimulatory versus inhibitory effects of progesterone on estrogen-induced PH LH and prolactin secretion correlated with estrogen nuclear and progestin cytosol receptor concentrations in brain and pituitary gland. Neuroendocrinology 42: 6–14.

14. Carr LA, Conway PM, Voogt JL (1975) Role of norepinephrine in the release of prolactin induced by suckling and estrogen. Brain Res 133: 505–514.

15. Chang RJ, Davidson BJ, Carlson HE, Judd HL (1982) Circadian pattern of prolactin secretion in postmenopausal women receiving estrogen with or without progestin. Am J Obstet Gynecol 144: 402–407.

16. Deyo SN, Miller RJ (1982) The role of endogenous opioids in the stress-and estrogen-induced activation of prolactin release. Life Sci 31: 2173–2175.

17. Zigone V, Meurier H, Veilleux R, Labrie F (1982) Direct effects of sex steroids on prolactin release at the anterior pituitary level: interactions with dopamine, thyrotropin-releasing hormone, and isobutylmethylxanthine. Endocrinology 111: 857–862.

18. Klobota T, Kuan SJ, MacLeod RM (1989) Effect of 17 beta-estradiol on phosphoinositide metabolism and prolactin secretion in anterior pituitary cells. Neuroendocrinology 50: 400–405.

19. Velhuis JD, Evans WS, Stumpf PG (1989) Mechanisms that subserve estradiol's induction of increased prolactin concentrations: evidence of amplitude modulation of spontaneous prolactin secretory bursts. Am J Obstet Gynecol 161: 1149–1158.

20. Perez RL, Machiavelli GA, Romano MI, Burdman JA (1986) Prolactin release, oocytes and proliferation of prolactin-secreting cells in the anterior pituitary gland of adult male rats. Endocrinology 118: 399–403.

21. Hickey GJ, Krawnow JS, Beatie WG, Richards JS (1990) Aromatase cytochrome P450 in rat ovarian granulosa cells before and after luteinization: adenosine

Hypophyseal Local Regulation of Prolactin Cells by Aromatase
3',5'-monophosphate-dependent and independent regulation. Cloning and sequencing of rat aromatase cDNA and 5' genomic DNA. Mol Endocrinol 4: 3-12.

22. Galmiche G, Corvaisier S, Kortler ML (2006) Aromatase gene expression and regulation in the female rat pituitary. Ann N Y Acad Sci 1070: 206-209.

23. Nolan LA, Levy A (2006) The effects of testosterone and oestrogen on gonadectomy and intact male rat anterior pituitary mitotic and apoptotic activity. J Endocrinol 180: 387-396.

24. Dada MO, Campbell GT, Blake CA (1984) Pars distalis cell quantification in normal adult male and female rats. J Endocrinol 101: 87-94.

25. Carretero J, vazquez G, blanco E, rubio M, santos M, et al. (1999) Immunohistochemical evidence of the presence of aromatase P450 in the rat hypophysis. Cell Tissue Res 293: 419-423.

26. Haug E, Gautvik KM (1976) Effects of sex steroids on prolactin secreting rat pituitary cells in culture. Endocrinology 99: 1482-1489.

27. Chowen JA, Gonzalez-Parra S, Garcia-Segura LM, Argente J (1998) Sexually dimorphic interaction of insulin-like growth factor (IGF)-I and sex steroids in lactotrophs. J Neuroendocrinol 10: 493-502.

28. Steele RE, Mellor LH, Sawyer WK, Wavary JM, Browne LJ (1987) In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A. Steroids 50: 147-161.

29. Bonsall RW, Clancy AN, Michael RP (1992) Effects of the nonsteroidal aromatase inhibitor Fadrozole, on sexual behavior in male rats. Horm Behav 26: 240-254.

30. Gunson DE, Steele RE, Chau RY (1995) Prevention of spontaneous tumours in female rats by fadrozole hydrochloride, an aromatase inhibitor. Br J Cancer 72: 72-75.

31. Tsai PS, Hayes TB, Licht P (1994) Role of aromatization in testosterone-induced inhibition of hetimezing hormone secretion in female turtles, Trachemys scripta. Biol Reprod 50: 144-151.

32. Macleod RM, Abad A, Edmon LH (1969) In vivo effect of sex hormones on the in vitro synthesis of prolactin and growth hormone in normal and pituitary tumor-bearing rats. Endocrinology 84: 1473-1483.

33. Maurer RA (1982) Estradiol regulates the transcription of the prolactin gene. J Biol Chem 257: 2133-2136.

34. Shull JD, Gorski J (1984) Estrogen stimulates prolactin gene transcription by a mechanism independent of pituitary protein synthesis. Endocrinology 114: 1530-1537.

35. Shull JD, Gorski J (1985) Estrogen regulates the transcription of the rat prolactin gene in vivo through at least two independent mechanisms. Endocrinology 116: 2456-2462.

36. Shull JD, Gorski J (1986) The hormonal regulation of prolactin gene expression: an examination of mechanisms controlling prolactin synthesis and the possible relationship of estrogen to these mechanisms. Vitam Horm 43: 197-249.

37. Shupnik MA, Baxter LA, French LR, Gorski J (1979) In vivo effects of estrogen on ovine pituitaries: prolactin and growth hormone biosynthesis and messenger ribonucleic acid translation. Endocrinology 104: 729-735.

38. Somaekhar MB, Gorski J (1980) Two elements of the rat prolactin 5' flanking region are required for its regulation by estrogen and glucocorticoids. Gene 69: 13-21.

39. Vician L, Shupnik MA, Gorski J (1979) Effects of estrogen on primary ovine pituitary cell cultures: stimulation of prolactin secretion, synthesis, and preprolactin messenger ribonucleic acid activity. Endocrinology 104: 736-743.

40. Carrillo AJ, Sharp ZD, DePaolo LV (1987) Correlation of rat pituitary prolactin messenger ribonucleic acid and hormone content with serum levels during the estrogen-induced surge. Endocrinology 121: 1993-1999.

41. Waterman ML, Adler S, Nelson C, Greene GL, Evans RM, et al. (1988) A single domain of the estrogen receptor confers deoxyribonucleic acid binding and transcriptional activation of the rat prolactin gene. Mol Endocrinol 2: 14-21.

42. Schaufle F (1999) Regulation of estrogen receptor activation of the prolactin enhancer/promoter by antagonistic activation function-2-interacting proteins. Mol Endocrinol 13: 935-945.

43. Lannigan DA, Notides AC (1990) Estrogen regulation of transcription. Prog Clin Biol Res 322: 187-197.

44. Maurer RA, Gorski J (1977) Effects of estradiol-17beta and pinoside on prolactin synthesis in male and female rats. Endocrinology 101: 76-84.

45. Burdman JA, Calabrese MT, Romano MJ, Carricarte VC, MacLeod RM (1984) Effect of ovarectomy and clomiphene on the in-vitro incorporation of [3H]thymidine into pituitary DNA and on prolactin synthesis and release in rats. J Endocrinol 101: 197-201.

46. Lieberman ME, Maurer RA, Gorski J (1978) Estrogen control of prolactin synthesis in vitro. Proc Nail Acad Sci U S A 75: 5946-5949.

47. Hymer WC, Mc SW, Christiansen RG (1961) Electron microscopic studies of anterior pituitary glands from lactating and estrogen-treated rats. Endocrinology 69: 81-90.

48. Pantic V, Genbaev O (1969) Ultrastructure of pituitary lactotrophic cells of oestrogen treated male rats. Z Zellforsch Mikrosk Anat 95: 280-289.

49. Saunders SL, Reif CW, Shin SH (1983) Ultrastructural changes rapidly induced by somatotam may inhibit prolactin release in estrogen-primed rat adenohypophysis. Cell Tissue Res 232: 21-34.

50. Smith RE, Farquhar MG (1966) Lysosome function in the regulation of the dependence upon dynamic state of the lactotroph. J Endocrinol 114: 213-220.

51. Goluboff LG, Earin C (1969) Effect of pregnancy on the somatotroph and the prolactin cell of the human adenohypophysis. J Clin Endocrinol Metab 29: 1533-1538.

52. Poole MC, Mahesh VB, Costoff A (1980) Intracellular dynamics in pituitary mammotropes throughout the rat estrous cycle. I. Morphometric methodology and hormonal correlations with cellular and nuclear volumes. Am J Anat 158: 3-13.

53. Amara JF, Van Itallie C, Dummies PS (1987) Regulation of prolactin production and cell growth by estradiol: difference in sensitivity to estradiol occurs at level of messenger ribonucleic acid accumulation. Endocrinology 120: 264-271.

54. Lloyd HM, Meares JD, Jacob J (1975) Effects of oestrogen and bromocrypine on in vivo secretion and mitosis in pituitary cells. Nature 253: 497-498.

55. Lloyd BV, Gamo M, Landefeld TD (1986) The effects of estrogens on tumor growth and on prolactin and growth hormone mRNA expression in pituitary tissues. Am J Pathol 133: 397-406.

56. Sakuma S, Shirasava N, Yoshimura F (1984) A histological study of immunohistochemically identified mitotic adenohypophysial cells in immature and mature castrated rats. J Endocrinol 100: 323-328.

57. Yamamoto N, Seo H, Suganuma N, Matsui N, Nakane T, et al. (1986) Effect of estrogen on prolactin mRNA in the rat pituitary. Analysis by in situ hybridization and immunohistochemistry. Neuroendocrinology 42: 494-497.

58. Carretero J, Rubio M, Sanchez F, Vazquez RJ, Santos M, et al. (1995) In vivo morphometric and proliferative variations in VIP-immunoreactive pituitary cells induced by estradiol. Neuroendocrinology 62: 277-282.